Skip to main content

Research Repository

Advanced Search

All Outputs (7)

Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer (2014)
Journal Article
Mavrou, A., Brakspear, K., Hamdollah-Zadeh, M., Damodaran, G., Babaei-Jadidi, R., Oxley, J., …Oltean, S. (2015). Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. Oncogene, 34(33), 4311-4319. https://doi.org/10.1038/onc.2014.360

Angiogenesis is required for tumour growth and is induced principally by vascular endothelial growth factor A (VEGF-A). VEGF-A pre-mRNA is alternatively spliced at the terminal exon to produce two families of isoforms, pro- and anti-angiogenic, only... Read More about Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer.

Regulation of alternative VEGF-A mRNA splicing is a therapeutic target for analgesia (2014)
Journal Article
Hulse, R., Beazley-Long, N., Hua, J., Kennedy, H., Prager, J., Bevan, H., …Donaldson, L. (2014). Regulation of alternative VEGF-A mRNA splicing is a therapeutic target for analgesia. Neurobiology of Disease, 71, 245-259. https://doi.org/10.1016/j.nbd.2014.08.012

Vascular endothelial growth factor-A (VEGF-A) is best known as a key regulator of the formation of new blood vessels. Neutralization of VEGF-A with anti-VEGF therapy e.g. bevacizumab, can be painful, and this is hypothesized to result from a loss of... Read More about Regulation of alternative VEGF-A mRNA splicing is a therapeutic target for analgesia.

Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance (2014)
Journal Article
Hamdollah Zadeh, M. A., Amin, E. M., Hoareau-Aveilla, C., Domingo, E., Symonds, K. E., Ye, X., …Bates, D. O. (2015). Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance. Molecular Oncology, 9(1), 167-178. https://doi.org/10.1016/j.molonc.2014.07.017

Antiangiogenic actions of vascular endothelial growth factor-A165b, an inhibitory isoform of vascular endothelial growth factor-A, in human obesity (2014)
Journal Article
Bates, D., Ngo, D. T. M., Farb, M. G., Kikuchi, R., Karki, S., Tiwari, S., …Gokce, N. (2014). Antiangiogenic actions of vascular endothelial growth factor-A165b, an inhibitory isoform of vascular endothelial growth factor-A, in human obesity. Circulation, 130(13), 1072-1080. https://doi.org/10.1161/CIRCULATIONAHA.113.008171

Background—Experimental studies suggest that visceral adiposity and adipose tissue dysfunction play a central role in obesity-related cardiometabolic complications. Impaired angiogenesis in fat has been implicated in the development of adipose tissue... Read More about Antiangiogenic actions of vascular endothelial growth factor-A165b, an inhibitory isoform of vascular endothelial growth factor-A, in human obesity.

Resolution of the three dimensional structure of components of the glomerular filtration barrier (2014)
Journal Article
Qvortrup, K., ARKILL, K., Starborg, T., Mantell, J., Knupp, C., Michel, C., …Neal, C. (2014). Resolution of the three dimensional structure of components of the glomerular filtration barrier. BMC Nephrology, 15(1), Article 24. https://doi.org/10.1186/1471-2369-15-24

Background: The human glomerulus is the primary filtration unit of the kidney, and contains the Glomerular Filtration Barrier (GFB). The GFB had been thought to comprise 3 layers - the endothelium, the basement membrane and the podocyte foot processe... Read More about Resolution of the three dimensional structure of components of the glomerular filtration barrier.